Paraldehyde

DB09117ApprovedWithdrawnSmall molecule

Paraldehyde is a central nervous system depressant previously used to control convulsions due to various clinical causes, including tetanus, status epilepticus, and convulsive drugs. Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.

Mechanism: Paraldehyde is believed to reduce the release of acetylcholine in response to neuronal depolarization. The exact mechanism of this effect is unknown.
Curator reviewed · 1 reference
Primary indication: Paraldehyde was used historically as a sedative and hypnotic.Curator reviewed
Formula / weight: C₆H₁₂O₃ · 132.1577 g/mol (avg)
First approval: Canada, 2008

Resolves to

Compound

UNIIS6M3YBG8QACAS123-63-7ChEMBLCHEMBL1410743ChEBI27909PubChem31264KEGGC07834

Clinical / RWD

RxNorm7909ATCN05CC05

Structure

InChIKeySQYNKIJPMDEDEG-UHFFFAOYSA-NSMILESCC1OC(C)OC(C)O1

What you can answer from here — as of March 06, 2025

813Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

4Marketed productsAcross 2 countries and 4 labellers

1ATC codeIncluding every combination product, plus 7 drug categories

5+ReferencesStructured and connected to the statements they support

Which companies are running trials of Paraldehyde, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account